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Abstract
We reviewed the COVID-19 vaccines that reached phase III of clinical development. For each of the 10 vaccines identified, we
described the technology used for vaccine development, the available data from phase III clinical trials, data on vaccine safety,
and the role of new SARS-CoV-2 variants on vaccine efficacy.
Introduction
There are exceptional ongoing efforts to develop effec-
tive vaccines against SARS-CoV-2 with the goal to con-
trol the current COVID-19 pandemic. According to the
World Health organization, as of March 1, 2021, there
are 182 vaccines in preclinical development and 74 vac-
cines in different phases of clinical development.[1]
We performed a literature review with the objective to
evaluate the vaccine efficacy, safety and technology of
the COVID-19 vaccines that have reached phase III of
clinical development.
Methods
Vaccines that reached phase III of clinical development
COVID-19 vaccines that had reached phase III of clini-
cal development were identified. These vaccines were
classified in two groups: the vaccines that completed
phase III studies (no longer recruiting participants),
and the vaccines in ongoing phase III studies (still re-
cruiting participants). These groups were further clas-
sified according to the quality of the data currently
available to review the efficacy and safety of each vac-
cine. Priority was given to data obtained from studies
published in peer-reviewed journals, followed by data
obtained from press release documents.
Vaccine technology
For each of the vaccines that reached phase III clinical
trials, the technology used for the development of the
vaccine was identified. These technologies fall into two
categories: protein-based vaccines, used to inject par-
ticipants with SARS-CoV-2 proteins; and gene-based
vaccines, used to inject participants with SARS-CoV-2
genetic material.
Vaccine phase III clinical trial data
The data from phase III clinical trials were summarized
for vaccines with data available from peer-reviewed
publications and vaccines with only press-released
data. The vaccines were ordered according to the num-
ber of COVID-19 cases used to calculate their efficacy,
prioritizing studies with a greater number of COVID-
19 cases. We also evaluated the generalizability of their
respective study data, as determined by the number of
study subjects and the number of countries participat-
ing in the trial.
Vaccine safety data
Data concerning the safety of the vaccines were ob-
tained from peer-reviewed publications as well as press
release documents.
Vaccine efficacy and SARS-CoV-2 variants
A review of peer-reviewed publications was performed
to evaluate vaccine efficacy in relation to emergent
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Figure 1. Vaccines that reached phase III of clinical development.
Figure 2. Phase III vaccines categorized by technology.
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SARS-CoV-2 variants.
Results
Vaccines that reached phase III of clinical development
We identified 10 vaccines that reached phase III of clini-
cal development. The classification of these 10 vaccines
vaccines according to phase III clinical trial status—
completed or ongoing—and availability of clinical trial
data are depicted in Figure 1.
Vaccine Technology
The technology used in the development of these 10
vaccines is depicted in Figure 2. Four vaccines used a
protein-based technology, and six vaccines used gene-
based technology.
Vaccine phase III clinical trial data
Four vaccines have completed phase III clinical trials
with data available in peer-reviewed journals. Our re-
view of the data from these clinical trials in relation
to vaccine efficacy, number of trial participants, num-
ber of cases of COVID-19, and location of trial sites is
described in Table 1.[2–7] We identified three vaccines
with phase III clinical trial data from press release doc-
uments. The review of the available data for these vac-
cines is described in Table 2.[8–12]
Vaccine safety data
Some recipients of the vaccines under discussion have
reported mild to moderate adverse events. Local ad-
verse events include pain at injection site, erythema,
pruritus and lymphadenopathy. Systemic adverse
events include fatigue, headache, fever, chills, nau-
sea and vomiting. The Pfizer vaccine was associ-
ated with four cases of severe adverse events, includ-
ing shoulder injury related to vaccine administration,
right axillary lymphadenopathy, paroxysmal ventric-
ular arrhythmia, and right leg paresthesia.[3] Initially,
three cases of transverse myelitis (TM) and one case of
multiple sclerosis (MS) were associated with Oxford-
AstraZeneca vaccine, in response to which, the study
was placed on temporary hold for careful independent
review of each case.[4] It was determined that only 1
case of TM in the vaccine group was a vaccine-related
adverse event, while the remaining 2 cases of TM—one
in the vaccine group, the other in placebo group—were
unrelated to the vaccine.[4] Further independent inves-
tigation revealed that the patient in the vaccine group
who developed MS 10 days after receiving the first dose
had pre-existing, underlying, unrecognized MS; thus,
this case was also found to be unrelated to the vac-
cine.[4]
Pfizer/BioNTech reported six deaths during their
study, two from the vaccine group and four from the
placebo group. However, the investigators concluded
that these deaths were not related to the vaccine or to
the placebo.[3] Gamaleya investigators reported three
deaths during the study, but none of these was reported
to be associated with the vaccine.[7] Johnson & Johnson
also reported three deaths that were not related to the
study.[8] Oxford-AstraZeneca reported five deaths, one
in the vaccine group and four in the placebo group.[4]
The death in the vaccine group was deemed unrelated
to the vaccine or to COVID-19, while in the placebo
group, there was one death due to severe COVID-19
leading to hospitalization 21 days after the first placebo
dose. The remaining three deaths in the placebo group
were unrelated to COVID-19 or to the vaccine.[4]
Vaccine efficacy and SARS-CoV-2 variants
Data on the potential efficacy of four vaccines against
new SARS-CoV-2 variants, as well as the origins of the
variants and the locations of their mutations, are de-
scribed in Table 3.[8–10, 13–17] There are currently no
available data on the impact of the new COVID-19 vari-
ants on the severity of the disease, but the UK vari-
ant (B.1.1.7) and Brazil variant (P.1) have been found
to be more transmissible than the original SARS-CoV-
2 virus.[13] In a recent study, the Pfizer/BioNTech
vaccine demonstrated poor efficacy against the South
Africa variant (B.1.351).[18]
Discussion
Here, we reviewed the available data on the 10 vac-
cines that have—as of March 1, 2021—reached phase
III of the clinical development process. Data from peer-
reviewed publications are available for only four vac-
cines. The existing evidence concerning vaccine effi-
cacy and safety is encouraging, but we still do not have
data on vaccine effectiveness and possible long-term
complications. As more vaccines come into the mar-
ket, it will be important to define which vaccines will
be the most effective in preventing COVID-19, as well
as achieving herd immunity.
The existing data on vaccine efficacy against the emerg-
ing SARS-CoV-2 variants are very limited. Only four
vaccines (Pfizer/BioNTech, Novavax, Johnson & John-
son, and Bharat Biotech) have demonstrated efficacy
against these variants; in the cases of Pfizer/BioNTech
and Novavax, these effects have only been documented
in vitro. No data are available on the efficacy of any
vaccine against the California variant (CAL.20C). Fu-
ture research should appraise COVID-19 vaccines on
the basis of variant coverage. With an increasingly
broad range of vaccines available, the potential risks
and benefits of combining different vaccines also re-
quire study.
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Table 1. Vaccines with peer-reviewed data.




Mod-NIH RNA 30,420 15,210 15,210 196 94.1 (89.3–96.8) USA 2 (28)
Pfi-BNT RNA 43,448 21,720 21,728 170 94.6 (89.9–97.3) USA, Germany, Turkey, South
Africa, Brazil, Argentina
2 (21)
Oxf-Ast Viral vector 23,848 12,082 11,766 131 70.4 (54.8–80.6) UK, South Africa, Brazil 2 (28)
Gamaleya Viral vector 21,977 16,501 5,476 78 91.6 (85.6–95.2) Russia 2 (21)
MOD-NIH: mRNA-1273, developed by Moderna and the National Institutes of Health.[2]
Pfi-BNT: BNT162b2, developed by Pfizer and BioNTech.[3]
Oxf-Ast: Covishield/ChAdOx1 nCoV-19 (AZD1222), developed by Oxford University and AstraZeneca.[4, 5]
Gamaleya: Sputnik V/Gam-COVID-Vac, developed by the Gamaleya Research Institute.[6, 7]
Table 2. Vaccines with press release data.
Vaccine Type Participants COVID-19Cases Efficacy (95% CI) Phase III Trial Site No. of doses
Enrolled Vaccine Placebo





Nov-HHS Recombinant spikeprotein nanoparticle
15,000 NA NA 62 (6:56)† 89.3% (75.2–95.4) UK
2
4,400∗ NA NA 44 (15:29)† 60% (19.9–80.1) South Africa
16,000 NA NA NA NA USA, Mexico
BB-NIV Whole-virion inactivated 25,800 NA NA NA NA India 2
J & J: Ad26.COV2-S, developed by Johnson & Johnson.[8, 9]
Nov-HHS: NVX-CoV2373, developed by Novavax and the Department of Health and Human Services.[10–11]
BB-NIV: Covaxin/BBV152, developed by Bharat Biotech and the National Institute of Virology.[12]
∗Phase 2b. †Total (vaccine:placebo)
Table 3. SARS-CoV-2 variants.
Name Origin Location of Mutations First Reported First Reported (US) Vaccine Effectiveness
B.1.1.7 [13] UK Mutation in RBD* of spike
protein at position 501:
amino acid asparagine (N)
replaced with tyrosine (Y).†
P618H replacement on the
spike proteins.
Deletion at positions 69 and
70 of spike protein.





Biotech (in vitro studies) [15]
B.1.351 [13] South Africa Eight lineage-defining muta-
tions in the spike protein
Spike protein, including
K417N, E484K, N501Y
South Africa, October 2020 January 2021 Pfizer/BioNTech (in vitro
studies) [14]
Janssen (Phase III trial, 95%




P.1 [13] Brazil 17 unique mutations, includ-
ing 3 in RBD of spike protein
Japan, January 2021 January 2021 Janssen [8, 9]
Novavax (NVX-CoV2373)
[10]
CAL.20C [16] USA (Southern CA) Cluster 20C consists of 5
mutations: ORF1a: I4205V,
ORF1b: D1183Y, S: S13I;
W152C; L452R (S13I and
W152C in the N-terminal do-
main, and L452R in RBD)
Los Angeles (CA), July 2020 July 2020 Unknown
∗Receptor binding domain †The shorthand for this mutation is N501Y
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